Seredigm was founded to commercialize proprietary compositions that protect against tissue damage in a variety of acute or chronic medical conditions. Tissue damage plays a critical role in the pathogenesis of diverse life-threatening conditions, including a variety of acute cardiac indications and chronic diseases such as multiple sclerosis and asthma.
Seredigm’s technology was developed in laboratories at the University of Washington and, under a collaboration agreement between Seredigm and the university, a significant amount of the company’s R&D activities will be conducted in these same laboratories.
Accelerator said that it plans to maintain Seredigm as a portfolio company from the technology’s preclinical proof-of-concept stage to the initiation of human clinical trials.
“Seredigm’s proprietary compositions have the potential to reduce or inhibit tissue damage, providing for the first time a mechanism for preventing a variety of diseases and chronic conditions, rather than just treating their symptoms. This would be a significant advance in patient care, and also creates a compelling investment opportunity,” commented Robert Nelsen, managing partner of ARCH Venture Partners, one of the companies leading the series A investment in Seredigm.